日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia

BCR::ABL1驱动的慢性粒细胞白血病的发生时间和轨迹

Kamizela, Aleksandra E; Leongamornlert, Daniel; Williams, Nicholas; Wang, Xin; Nyamondo, Kudzai; Dawson, Kevin; Spencer Chapman, Michael; Guo, Jing; Lee, Joe; Mane, Karim; Milne, Kate; Green, Anthony R; Chevassut, Timothy; Campbell, Peter J; Ellinor, Patrick T; Huntly, Brian J P; Baxter, E Joanna; Nangalia, Jyoti

Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse.

基于 ISOX-DUAL 的结构导向降解剂设计:针对 BRD4 和 CBP/EP300 的降解剂崩溃案例

Edmonds Anthony K, Balourdas Dimitrios-Ilias, Marsh Graham P, Felix Robert, Brasher Bradley, Cooper Jeff, Graber-Feesl Cari, Kollareddy Madhu, Malik Karim, Stewart Helen, Chevassut Timothy J T, Lineham Ella, Morley Simon, Fedorov Oleg, Bennett James, Rajasekaran Mohan B, Ojeda Samuel, Harrison Drew A, Ott Christopher J, Joerger Andreas C, Maple Hannah J, Spencer John

A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome

一项针对骨髓增生异常综合征患者的1期研究,评估度伐利尤单抗单药治疗或联合曲美利木单抗(加或不加阿扎胞苷)的疗效。

Garcia-Manero, Guillermo; Gaddh, Manila; Platzbecker, Uwe; Lindsley, R Coleman; Larson, Sarah M; Chevassut, Timothy; Fenaux, Pierre; Komrokji, Rami; Lyons, Roger; Al-Kali, Aref; Jiang, Yu; Bothos, John; Townsley, Danielle M; Zeidan, Amer M

Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data

患者特异性计算模型通过量化基因测序数据中的促增殖和抗凋亡特征来预测B细胞淋巴瘤的预后。

Norris, Richard; Jones, John; Mancini, Erika; Chevassut, Timothy; Simoes, Fabio A; Pepper, Chris; Pepper, Andrea; Mitchell, Simon

Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma

剖析溴结构域抑制剂对多发性骨髓瘤中干扰素调节因子 4-MYC 致癌轴的影响

Alessandro Agnarelli, Simon Mitchell, Gillian Caalim, C David Wood, Leanne Milton-Harris, Timothy Chevassut, Michelle J West, Erika J Mancini

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

口服阿扎胞苷治疗缓解期急性髓系白血病患者的不良事件管理:来自 QUAZAR AML-001 3 期随机试验的经验

Ravandi, Farhad; Roboz, Gail J; Wei, Andrew H; Döhner, Hartmut; Pocock, Christopher; Selleslag, Dominik; Montesinos, Pau; Sayar, Hamid; Musso, Maurizio; Figuera-Alvarez, Angela; Safah, Hana; Tse, William; Sohn, Sang Kyun; Hiwase, Devendra; Chevassut, Timothy; Pierdomenico, Francesca; La Torre, Ignazia; Skikne, Barry; Bailey, Rochelle; Zhong, Jianhua; Beach, C L; Dombret, Herve

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target

慢性淋巴细胞白血病中的 TLR9 表达可识别出一种迁移亚群和新的治疗靶点

Emma Kennedy, Eve Coulter, Emma Halliwell, Nuria Profitos-Peleja, Elisabeth Walsby, Barnaby Clark, Elizabeth H Phillips, Thomas A Burley, Simon Mitchell, Stephen Devereux, Christopher D Fegan, Christopher I Jones, Rosalynd Johnston, Tim Chevassut, Ralph Schulz, Martina Seiffert, Angelo Agathanggelou

BRD4-mediated repression of p53 is a target for combination therapy in AML

BRD4介导的p53抑制是急性髓系白血病联合治疗的靶点。

Anne-Louise Latif ,Ashley Newcombe ,Sha Li ,Kathryn Gilroy ,Neil A Robertson ,Xue Lei ,Helen J S Stewart ,John Cole ,Maria Terradas Terradas ,Loveena Rishi ,Lynn McGarry ,Claire McKeeve ,Claire Reid ,William Clark ,Joana Campos ,Kristina Kirschner ,Andrew Davis ,Jonathan Lopez ,Jun-Ichi Sakamaki ,Jennifer P Morton ,Kevin M Ryan ,Stephen W G Tait ,Sheela A Abraham ,Tessa Holyoake ,Brian Higgins ,Xu Huang ,Karen Blyth ,Mhairi Copland ,Timothy J T Chevassut ,Karen Keeshan ,Peter D Adams

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia

急性髓系白血病的生存环境:急性髓系白血病的骨髓微环境

Ladikou, E E; Sivaloganathan, H; Pepper, A; Chevassut, T

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived

2020年的慢性淋巴细胞白血病:未来已至

Milne, Kate; Sturrock, Beattie; Chevassut, Timothy